Statins may prevent cardiac dysfunction in patients taking anthracyclines

Neilan and colleagues conducted the double-blind, randomized, placebo-controlled STOP-CA trial to evaluate the effect of atorvastatin compared with placebo on the occurrence of cardiac dysfunction among patients with lymphoma treated with anthracyclines. Compared with placebo, atorvastatin was assoc...

Full description

Saved in:
Bibliographic Details
Published inCardiology Today Vol. 26; no. 3; p. 17
Main Author Buzby, Scott
Format Trade Publication Article
LanguageEnglish
Published Thorofare SLACK INCORPORATED 01.03.2023
Subjects
Cardiology
Lymphoma
Online AccessGet full text

Cover

More Information
Summary:Neilan and colleagues conducted the double-blind, randomized, placebo-controlled STOP-CA trial to evaluate the effect of atorvastatin compared with placebo on the occurrence of cardiac dysfunction among patients with lymphoma treated with anthracyclines. Compared with placebo, atorvastatin was associated with lower incidence of the primary outcome in subgroups including women (P = .024), age older than 52 years (P = .03), patients who received lower cumulative anthracycline treatment (< 250 mg/m2; P = .011) and patients with BMI of at least 30 kg/m2(P = . There were no between-group differences in adverse events. - by Scott Buzby ¦ Disclosure: Neilan reports receiving consultant fees and/or honoraria from AbbVie, Amgen, Bristol Myers Sguibb, CRC Oncology, Cenentech, Intrinsic Imaging, Parexel, Roche and Sanofi Aventis and research grants from AstraZeneca and Bristol Myers Sguibb PERSPECTIVE The most important take-home message from the STOP-CA trial is that statins potentially could help attenuate the drop in the EF among patients exposed to anthracyclines for lymphoma.
ISSN:1939-098X